<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00196209</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE No. C00705</org_study_id>
    <nct_id>NCT00196209</nct_id>
  </id_info>
  <brief_title>Cardioversion vs. Catheter Ablation for Persistent Atrial Fibrillation</brief_title>
  <official_title>Randomized Study Comparing Cardioversion vs. Catheter Ablation in Patients With Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this randomized study is to evaluate the efficacy of two different approaches for
      conversion of persistent atrial fibrillation, the non-invasive one (external electrical
      cardioversion) and the invasive one (catheter ablation).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized study compares two treatment strategies in patients with persistent atrial
      fibrillation: Cardioversion vs. catheter ablation. Cardioversion is a low risk standard
      treatment option for patients with persistent atrial fibrillation. However, mid- and long
      term efficacy (regarding the maintenance of sinus rhythm) is low. Catheter ablation is an
      invasive treatment which has been reported to result in up to 60-70% of patients in stable
      sinus rhythm. However, it is a potentially dangerous invasive procedure with potentially
      fatal complications.

      Comparison: External cardioversion vs. catheter ablation
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2005</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival after 6 months (i.e. freedom of atrial tachyarrhythmias - as evaluated in a 7-d-holter, stroke, pulmonary vein stenosis - as evaluated in a CT-/MRT-scan 6 months after the initial procedure - and death).</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>success-rate immediately after intervention</measure>
    <time_frame>success-rate immediately after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for re-intervention between 2 and 3 months after initial procedure if not stable sinus rhythm at the two-months follow-up (further ablation/cardioversion)</measure>
    <time_frame>2-3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>burden of atrial fibrillation in a 7-day-holter after 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>significant improvement in exercise capacity (measured by spiroergometry)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>decrease in NT-pro-BNP levels in the blood after 6 months compared to the level before initial intervention</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement of quality-of-life (combined questionnaire including the SF-36 form) before initial intervention and at the 6-months follow-up</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>catheter ablation to treat persistent atrial fibrillation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cardioversion and drug prophylaxis to treat persistent atrial fibrillation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>catheter ablation</intervention_name>
    <description>catheter ablation to treat persistent atrial fibrillation</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>external electric cardioversion</intervention_name>
    <description>external cardioversion and drug prophylaxis to treat persistent atrial fibrillation</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;20 years and &lt;75 years

          -  documented persistent atrial fibrillation for at least 3 months (documented in at
             least 2 ECGs or holter-ECGs during the previous 3 months before inclusion and
             persistent atrial fibrillation in a 7-d-holter)

          -  documented sufficient anticoagulation for at least 4 weeks before inclusion

        Exclusion Criteria:

          -  Paroxysmal atrial fibrillation

          -  NYHA IV (if recompensation is not possible)

          -  Contraindication for warfarin

          -  Disturbance of blood coagulation

          -  Myocardial infarction, PTCA/stenting, bypass-operation, stroke, intracranial bleeding
             less than 3 months before

          -  Reversible causes of atrial fibrillation (i.e. hyperthyroidism)

          -  Pregnancy

          -  LA-diameter &gt; 55mm

          -  LV-function &lt; 30% EF

          -  Aortic or mitral stenosis or regurgitation III°-IV°

          -  Prosthetic valves
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabel Deisenhofer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heidi L Estner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heidi L Estner, MD</last_name>
    <phone>0049 89 1218 2020</phone>
    <email>estner@dhm.mhn.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi L. Estner, MD</last_name>
      <phone>0049 89 1218-2020</phone>
      <email>estner@dhm.mhn.de</email>
    </contact>
    <investigator>
      <last_name>Heidi L Estner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>March 18, 2008</last_update_submitted>
  <last_update_submitted_qc>March 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2008</last_update_posted>
  <responsible_party>
    <name_title>Prof. A. Schömig</name_title>
    <organization>Deutsches Herzzentrum Munich</organization>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>catheter ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

